| Effect of chronic oral domperidone therapy on gastrointestinal symptoms and gastric emptying in patients with Parkinson's disease. | |
| | |
MedLine Citation:
|
PMID: 9399220 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
This study investigated whether domperidone could improve gastrointestinal symptoms in patients with Parkinson's disease who were receiving levodopa therapy. A total of 11 patients were studied. Following a baseline gastric emptying test, patients were treated with a starting dose of domperidone 20 mg p.o. q.i.d. A follow-up gastric emptying test was repeated at least 4 months after starting domperidone therapy. At the beginning and at each 3-month follow-up visit, symptoms of nausea, vomiting, anorexia, abdominal bloating, heartburn, regurgitation, dysphagia, and constipation were evaluated and scored on a scale of 0-3. The overall mean follow-up period was 3 years. Compared with their baseline evaluation, patients experienced a significant improvement in all symptoms (p < 0.05) except dysphagia and constipation. Gastric emptying of an isotope-labeled solid meal was significantly faster, with a baseline result of 60.2 +/- 6.4% retention of isotope 2 h after the meal compared with 37.0 +/- 2.2% retention during domperidone therapy (p < 0.05). Patients' global assessment of Parkinson's disease remained stable or improved. Serum prolactin was elevated in all patients after domperidone therapy (p < 0.05). Domperidone therapy significantly reduces upper gastrointestinal symptoms and accelerates gastric emptying of a solid meal, but does not interfere with response to antiparkinsonism treatment. |
| | |
Authors:
|
I Soykan; I Sarosiek; J Shifflett; G F Wooten; R W McCallum |
Publication Detail:
|
Type: Clinical Trial; Journal Article |
Journal Detail:
|
Title: Movement disorders : official journal of the Movement Disorder Society Volume: 12 ISSN: 0885-3185 ISO Abbreviation: Mov. Disord. Publication Date: 1997 Nov |
Date Detail:
|
Created Date: 1998-02-10 Completed Date: 1998-02-10 Revised Date: 2004-11-17 |
Medline Journal Info:
|
Nlm Unique ID: 8610688 Medline TA: Mov Disord Country: UNITED STATES |
Other Details:
|
Languages: eng Pagination: 952-7 Citation Subset: IM |
Affiliation:
|
Department of Medicine, University of Virginia, Charlottesville, USA. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Aged Antiparkinson Agents / therapeutic use Bromocriptine / therapeutic use Carbidopa / therapeutic use Domperidone / pharmacology*, therapeutic use* Dopamine Antagonists / pharmacology*, therapeutic use* Drug Therapy, Combination Female Follow-Up Studies Gastric Emptying / drug effects* Gastrointestinal Diseases / complications*, drug therapy* Humans Levodopa / therapeutic use Male Middle Aged Parkinson Disease / complications*, drug therapy Selegiline / therapeutic use Severity of Illness Index |
| Chemical | |
Reg. No./Substance:
|
0/Antiparkinson Agents; 0/Dopamine Antagonists; 0/Levodopa; 14611-51-9/Selegiline; 25614-03-3/Bromocriptine; 38821-49-7/Carbidopa; 57808-66-9/Domperidone |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Constipation in Parkinson's disease: objective assessment and response to psyllium.
Next Document: Interlimb coordination deficits in patients with Parkinson's disease during the production of two-jo...